Medical Devices Startups

Expedition Therapeutics is a drug development company focused on advancing therapeutic programs in areas such as CAR-T immunotherapy and oncology. The company serves patients and healthcare systems seeking novel treatment options.

1 investor

Experic is a CDMO (Contract Development and Manufacturing Organization) specializing in inhalation pharmaceutical product development, formulation engineering, and clinical manufacturing services. The company provides process development, analytical testing, technology transfer, and scale-up support for inhalation drugs and encapsulated solid dose pharmaceuticals.

1 investor

Voxia is a wearable control interface that converts intentional vocal cord activation, such as a hum, into real-time input, allowing people with severe motor and speech impairments (e.g. ALS, stroke, cerebral palsy, Parkinson's) to operate AAC software, computers, tablets, and smart home devices. It is a medical device in development targeting Health Canada and US FDA clearance, aimed at patients who have exhausted conventional access technologies.</parameter> <parameter name="hq_country">CA

1 investor

EXPIN develops AI-driven tools for clinicians to analyze exposome data—the lifetime accumulation of environmental, chemical, and lifestyle exposures—to enable precision medicine for chronic disease prevention and treatment. The company serves healthcare providers and patients seeking to understand how non-genetic factors drive disease at the molecular level.

1 investor

ExploraMed is a medical device incubator that develops new med tech companies and products from early-stage concept through development. Its portfolio includes ventures such as Revelle Aesthetics, an aesthetics medical device company acquired by Tiger Aesthetics in 2024.

1 investor

Exprimary develops bioanalytical instrumentation and assay products at reduced cost for research and diagnostic markets. The company focuses on enabling personalized healthcare by improving access to bioanalysis tools globally.

1 investor

Exubrion Therapeutics develops veterinary therapies using conversion electron therapy from Tin-117m to treat pain and inflammation in companion animals. Its initial product, Synovetin OA, is a minimally invasive intra-articular injection for canine elbow osteoarthritis, marketed to veterinarians and pet owners.

1 investor

Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform. The company aims to reduce treatment burden for patients by extending the duration between required injections while improving disease control and visual outcomes.

1 investor

EyeCheckup is an AI-powered eye scanning system that diagnoses retinal diseases, cardiovascular disease, and chronic kidney disease from retinal fundus images. The company serves eye clinics, hospitals, health centers, and aims to increase screening access for the billions of people worldwide who need annual eye exams.

1 investor

Eye to Eye Telehealth develops technology to address data gaps in glaucoma care, working with engineers and clinicians to improve monitoring and treatment. It focuses on telehealth solutions for glaucoma management.

1 investor

EyeBuddy develops AI tools for early detection of eye diseases that work alongside clinicians in hospitals and eye care facilities. The company serves ophthalmologists and healthcare providers in Canada, South Asia, and the UK, with a focus on making eye care accessible to underserved populations.

1 investor

EyeCare Partners operates a network of over 1,000 eye care providers across the United States, offering a full continuum of vision care services including ophthalmology and optometry. The doctor-led organization combines individual practice autonomy with centralized resources to improve patient outcomes and accessibility.

1 investor

EyeCheck develops vision screening tools to identify refractive errors and expand access to eye care for underserved populations globally.

1 investor

CHV is a venture capital firm that invests in medical technology companies developing therapeutic devices, diagnostic tools, and digital health solutions to improve patient outcomes.

1 investor

EyeD Pharma develops pharmaceutical treatments focused on ophthalmology, particularly for glaucoma and related eye conditions. The company serves ophthalmologists and eye care professionals in treating patients with vision-related diseases.

1 investor

Eyenuk provides autonomous AI-based eye exams performed at the point of care to detect eye conditions including diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucomatous signs. Its technology holds regulatory clearances such as a Class IIb CE mark under EU MDR and maintains SOC 2 Type 2, HIPAA, and GDPR compliance.

1 investor

EyeSouth manages business operations for healthcare providers, allowing them to focus on delivering clinical care. The company serves optometry and ophthalmology practices.

1 investor

Eyetronic develops a non-invasive electrical stimulation therapy and system for patients with progressive visual field loss caused by glaucoma or other optic nerve diseases. The CE-marked therapy applies alternating pulses to stimulate retinal ganglion cell neurons and is offered in selected European treatment centers.

1 investor

Eyexora is a pharmaceutical company focused on ophthalmology and eye care treatments, serving patients and healthcare providers in the therapeutic and biologics space. The company develops and commercializes therapies for conditions including glaucoma and geographic atrophy.

1 investor

Eywa Pharma develops and manufactures generic drugs across multiple therapeutic areas and dosage forms, including tablets, capsules, and oral suspensions, for patients and pharmacies. It sells products under the Eywa label in the U.S. and the Zista name in the UK, with development in Chennai, India and manufacturing in Cranbury, New Jersey.

1 investor

FREST is a Japanese biotech venture developing RNA editing technology (RNA editing nucleic acids) that edits gene structure at the mRNA level to create nucleic acid drugs for genetic and currently untreatable diseases. The company partners with medical professionals, researchers, and pharmaceutical companies to apply this drug discovery technology.

1 investor

FA International provides technology and business development advisory services for industrial and medical device companies, helping them evaluate pre- and post-investment opportunities and technology risks to optimize returns and develop growth strategies.

1 investor

Farmako delivers prescription medicines to customers in 30 minutes via mobile app and WhatsApp in India. The company operates licensed retail pharmacy stores in Gurgaon and Moradabad, and also partners with diagnostic labs to provide lab testing and health records services.

1 investor

Faxitron makes the Faxitron Path (PathVision) specimen radiography system, which gives pathologists high-resolution X-ray imaging and reporting of tissue samples. The system is used in pathology labs to image specimens such as breast tissue and mastectomies, bones, and other samples to support accurate diagnoses.

1 investor